biostudies-literatureUnknown12(1)Darvishi-Khezri HThe Ministry of Health and Medical Education funds the Thalassemia Registry.Ferritin is frequently used to screen some dire consequences of iron overload in β-thalassemia patients. The study aimed to define the best cutoff point of ferritin to screen for cardiac and liver hemosiderosis in these cases. This was a registry-based study on β-thalassemia patients living throughout Mazandaran province, Iran (n = 1959). In this diagnostic research, the index test was ferritin levels measured by a chemiluminescent immunoassay. As a reference test, T2*-weighted magnetic resonance imaging (T2*-weighted MRI) was applied to determine cardiac and liver hemosiderosis. A cutoff point of 2027 ng/mL for ferritin showed a sensitivity of 50%, specificity 77.4%, PPV 42.1%, and NPV 82.5% for cardiac hemosiderosis (area under curve [AUC] 0.66, 95% CI 0.60-0.71, adjusted odds ratio [OR]Scientific reports17996https://www.ebi.ac.uk/biostudies/studies/S-EPMC9606378biostudies-literatureFerritin thresholds for cardiac and liver hemosiderosis in β-thalassemia patients: a diagnostic accuracy study.PMC9606378Kosaryan MAliasgharian AFallah HDarvishi-Khezri HNaderisorki MGhazaiean MZahedi MKarami HfalseFerritin thresholds for cardiac and liver hemosiderosis in β-thalassemia patients: a diagnostic accuracy study.Ferritin is frequently used to screen some dire consequences of iron overload in β-thalassemia patients. The study aimed to define the best cutoff point of ferritin to screen for cardiac and liver hemosiderosis in these cases. This was a registry-based study on β-thalassemia patients living throughout Mazandaran province, Iran (n = 1959). In this diagnostic research, the index test was ferritin levels measured by a chemiluminescent immunoassay. As a reference test, T2*-weighted magnetic resonance imaging (T2*-weighted MRI) was applied to determine cardiac and liver hemosiderosis. A cutoff point of 2027 ng/mL for ferritin showed a sensitivity of 50%, specificity 77.4%, PPV 42.1%, and NPV 82.5% for cardiac hemosiderosis (area under curve [AUC] 0.66, 95% CI 0.60-0.71, adjusted odds ratio [OR]2022-01-01T00:00:00Z2022 Oct2025-04-26T11:58:35.59Z2024-10-18T03:22:53.365ZS-EPMC96063783628926410.1038/s41598-022-22234-9